WASHINGTON, Dec. 11, 2014 /PRNewswire/ -- Ahead of an institutional investor and analyst meeting to be held in New York, Danaher Corporation (NYSE:DHR) reaffirmed the Company's GAAP diluted net earnings per share guidance of $1.00 to $1.04 for the fourth quarter 2014.Â
The Company anticipates that 2015 adjusted di
WASHINGTON, Dec. 11, 2014 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announces that today it will settle the public tender offer for all the registered shares of Nobel Biocare Holding AG ("Nobel Biocare").Â The additional acceptance period for the tender offer expired on December 4, 2014.Â
WASHINGTON, Dec. 10, 2014 /PRNewswire/ --Â Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly dividend of $0.10 per share payable on January 30, 2015 to holders of record on December 26, 2014.
WASHINGTON, Dec. 8, 2014 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) will host a live video webcast of its Investor and Analyst Meeting on December 11, 2014 beginning at 12:30 p.m. ET and concluding at approximately 4:30 p.m. The company previously communicated a 1:00 p.m. webcast start time. The link to the webcast can be found on the Investors section of Danaher's website, www.danaher.com, under "Investor Events." A replay of the video webcast will be available following the presentation.
Meeting agenda:11:30 AM:Â
WASHINGTON, Nov. 12, 2014 /PRNewswire/ --Â Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will present at the Baird Industrial Conference in Chicago, Illinois today, Wednesday, November 12 at 8:30 a.m. CT. The audio will be simultaneously webcast and the presentation will be archived on the Investors section of www.danaher.com under Investor Events.
The Company also announced that beginning in
WASHINGTON, Oct. 13, 2014 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today a definitive agreement with NetScout Systems, Inc. ('NetScout") (NASDAQ: NTCT) to combine Danaher's Communications business with NetScout in a tax-free transaction, creating a premier global provider of network management tools and security solutions for carrier and enterprise customers. At the closing of the transaction, Danaher shareholders will receive approximately 60% of the issued and outstanding shares of NetScout after giving effect to the transaction. At NetScout's closing price of $41.91 on October 10, 2014, the transaction values Danaher's Communications business at $2.6 billion.
Danaher's Communications business includes the market-leading brands of Tektronix Communications, Fluke Networks, and Arbor Networks. The data cabling tools business and carrier service provider tools business of Fluke Networks will be excluded from the transaction. Danaher's Communications business, excluding the previously mentioned Fluke Networks assets, generated approximately $836 million in revenue for their fiscal year ended December 2013, while NetScout generated approximately $397 million in revenue for their fiscal year ended March 2014.
Anil Singhal, Co-founder, President, and CEO of NetScout stated, "This combination represents another important step, and major milestone, towards accelerating our ability to compete on a larger and more global scale in the broader IT management and Cyber Intelligence space, to fully implement our NetScout 3.0 strategy, and to maximize our potential in our total addressable market."
Washington, D.C., September 22, 2014 - Danaher Corporation (NYSE:DHR) announced today that it will webcast its quarterly earnings conference call for the third quarter 2014 on Thursday, October 16, 2014 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
WASHINGTON, Sept. 15, 2014 /PRNewswire/ --Â Danaher Corporation (NYSE:DHR) has entered into a definitive transaction agreement with Nobel Biocare Holding AG ("Nobel Biocare") (SIX Swiss Exchange: NOBN) pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries ("Danaher") will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion.Â The deal is expected to widen Danaher's market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth.
Under the terms of the transaction agreement, Danaher will commence a voluntary all-cash public tender offer of CHF 17.10 per Nobel Biocare share to purchase all of Nobel Biocare's publicly held registered shares. Â The pre-announcement of the public tender offer is published today.Â The offer prospectus is expected to be published on or around October 1, 2014 and the offer period during which Nobel Biocare shareholders may tender their registered shares is expected to start on or around October 16, 2014.Â Headquartered in